From cGMP products for APIs to advanced materials in semiconductors and OLEDs, leading industries trust Cambridge Isotope Laboratories, Inc. (CIL) isotopes to enhance quality and performance. This commercial momentum has shaped CIL’s mission, fueling expansion and technological investment across its global footprint.

Over the past decade, advanced materials and technologies have further propelled CIL to the top of the stable isotope field. While CIL’s products remain fundamental to research, commercial demand—in pharmaceuticals, electronics, diagnostics, and quantum technology—has driven the company’s leadership position.

In diagnostics CIL’s ¹³C urea is the benchmark for ¹³C urea breath tests (UBTs), enabling hospitals and labs worldwide to reliably detect Helicobacter pylori and improve patient care.

CIL’s ultra-high purity 12C methane gas is now critical in the quantum diamond market, supporting the production of synthetic diamond substrates for quantum sensing and computing.

From deuterated drugs in pharma to advanced materials in semiconductors and OLEDs, leading industries trust CIL’s isotopes to enhance quality and performance. This commercial momentum has shaped CIL’s mission, fueling expansion and technological investment across its global footprint.

With more than 11,000 products and a track record of quality and partnership, CIL is the leading supplier for commercial industries, supporting advances in technology, medicine, and diagnostics around the globe.

Advanced Materials & Technologies Team

Team Leads

Cliff Caldwell

CEO

CCaldwell@isotope.com

Greg Whitney

Vice President
Sales and Marketing

GWhitney@isotope.com

Tasha Agreste

Director of Business Development
Deuterated Reagents

Tashaa@isotope.com

Joel Louette

Director of Business Development
Emerging Markets

JLouette@isotope.com

Krista Backiel

Director of Business Development 
and Strategic Marketing
Life Sciences

KristaB@isotope.com

Jack Faught

Product Manager – sales

jfaught@isotope.com